Patents by Inventor Michael Philbrook
Michael Philbrook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11793749Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: GrantFiled: August 20, 2021Date of Patent: October 24, 2023Assignee: Genzyme CorporationInventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
-
Publication number: 20220110861Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: ApplicationFiled: August 20, 2021Publication date: April 14, 2022Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
-
Publication number: 20220017853Abstract: Provided herein are compositions and formulations that are useful for stabilizing one or more bacteria (e.g., through drying). Methods of stabilizing the one or more bacteria are also disclosed.Type: ApplicationFiled: December 5, 2019Publication date: January 20, 2022Applicant: Seres Therapeutics, Inc.Inventors: Robert K. EVANS, Carl Michael PHILBROOK, Brian Michael SCHUSTER, Lisa MARSHALL
-
Patent number: 11110055Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: GrantFiled: January 4, 2019Date of Patent: September 7, 2021Assignee: Genzyme CorporationInventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
-
Publication number: 20200048222Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: ApplicationFiled: January 4, 2019Publication date: February 13, 2020Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos
-
Patent number: 10219998Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: GrantFiled: December 17, 2015Date of Patent: March 5, 2019Assignee: Genzyme CorporationInventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
-
Publication number: 20180104180Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminolycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.Type: ApplicationFiled: May 23, 2017Publication date: April 19, 2018Inventors: Kuber T. Sampath, Michael Philbrook, Aviva Shiedlin, John M. McPherson
-
Publication number: 20180000728Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.Type: ApplicationFiled: December 17, 2015Publication date: January 4, 2018Applicant: GENZYME CORPORATIONInventors: Harvey LIEBERMAN, Donglai YANG, C. Michael PHILBROOK, Michael SANTOS, Chris HO
-
Publication number: 20170281641Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-receptor kinase B (TrkB), tropomyosin-receptor kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).Type: ApplicationFiled: September 2, 2015Publication date: October 5, 2017Inventors: Kerry DONAHUE, C. Michael PHILBROOK, Dominick BLASIOLI, John L. KANE, Carl FLANNERY
-
Publication number: 20140271471Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminoglycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Genzyme CorporationInventors: Kuber T. Sampath, Michael Philbrook, Aviva Shiedlin, John M. McPherson
-
Publication number: 20130251683Abstract: The present invention relates to a heparin-derivatized collagen matrix comprising a fragment of heparin covalently linked to a collagen scaffold, wherein the fragment of heparin has molecular weight of less than about 15 kDa, and at least one heparin-binding growth factor (HBGF) or heparin-binding adeno-associated virus (HB-AAV) or a combination thereof and methods for promoting bone growth, bone repair, cartilage repair, bone development, neo-angiogensis, wound healing, tissue engraftment and muscle tissue regeneration and/or tissue augmentation comprising administering a heparin-derivatized collagen matrix that includes at least one heparin-binding growth factor or heparin-binding adeno-associated virus or a combination thereof.Type: ApplicationFiled: February 7, 2013Publication date: September 26, 2013Applicant: GENZYME CORPORATIONInventors: Michael Santos, Michael Philbrook, Michael A. DiMicco, Robert J. Miller
-
Publication number: 20120207847Abstract: This invention relates to compositions, methods of preparation thereof, and use thereof for cartilage repair.Type: ApplicationFiled: August 10, 2010Publication date: August 16, 2012Applicant: GENZYME CORPORATIONInventors: Timothy J. Butler, Michael Philbrook, Peter K. Jarrett
-
Publication number: 20120138195Abstract: The invention relates to a method for manufacturing a product comprising an AlCu alloy comprising (weight per cent): Cu: 3.8-5.5 Mg: 0.2-0.8 Mn: 0.2-0.6 Ag 0.2-0.5 Si<0.15 Fe<0.20 Zn<0.25 Cr<0.05 Zr<0.10, Ti<0.15 others <0.05, remainder aluminium. In an embodiment the method comprises naturally aging the product forming in at least one process, such as stretch forming, drawing, flow spinning, and/or bending and artificial aging at a temperature from 280 to 340° F. (138 to 171° C.) for a duration from 6 to 36 hours. The method is particularly useful to make armor products.Type: ApplicationFiled: December 1, 2011Publication date: June 7, 2012Applicant: CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLCInventors: Michael PHILBROOK, Michael M. NIEDZINSKI
-
Publication number: 20120088721Abstract: This invention relates to compositions, methods of preparation thereof, and use thereof for cartilage repair.Type: ApplicationFiled: March 22, 2010Publication date: April 12, 2012Applicant: GENZYME CORPORATIONInventors: Aviva Shiedlin, Timothy J. Butler, Michael Philbrook, Peter K. Jarrett
-
Publication number: 20090192079Abstract: The present invention relates to a heparin-derivatized collagen matrix comprising a fragment of heparin covalently linked to a collagen scaffold, wherein the fragment of heparin has molecular weight of less than about 15 kDa, and at least one heparin-binding growth factor (HBGF) or heparin-binding adeno-associated virus (HB-AAV) or a combination thereof and methods for promoting bone growth, bone repair, cartilage repair, bone development, neo-angiogensis, wound healing, tissue engraftment and muscle tissue regeneration and/or tissue augmentation comprising administering a heparin-derivatized collagen matrix that includes at least one heparin-binding growth factor or heparin-binding adeno-associated virus or a combination thereof.Type: ApplicationFiled: October 9, 2008Publication date: July 30, 2009Applicant: Genzyme CorporationInventors: Michael Santos, Michael Philbrook, Michael A. DiMicco, Robert J. Miller
-
Patent number: 7250177Abstract: Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.Type: GrantFiled: June 22, 2005Date of Patent: July 31, 2007Assignee: Genzyme CorporationInventors: Chandrashekhar P. Pathak, Shikha P. Barman, C. Michael Philbrook, Amarpreet S. Sawhney, Arthur J. Coury, Luis Z. Avila, Mark T. Kieras
-
Patent number: 7238532Abstract: A method for measuring the concentration of isothiazolones in aqueous systems including removing sample interferences by lowering the pH of a sample collected from the aqueous system containing isothiazolones and filtering the sample, removing additional interferences by raising the pH and subsequent filtering, selectively adsorbing the isothiazolones in the sample desorbing the isothiazolones from the adsorbent, and comparing the absorbance of ultra-violet light of the desorbed sample to a standard of known concentration.Type: GrantFiled: June 3, 2002Date of Patent: July 3, 2007Inventor: David Michael Philbrook
-
Patent number: 7074424Abstract: Hyaluronic acid and polyalkylene glycol (PAG) based materials have been found to exhibit a synergistic interaction, in which the viscosity of the mixture is more than twice as high as the viscosity expected from the viscosity of the individual components. The mixture otherwise has similar properties to those of its constituents, and in particular will crosslink to form covalently crosslinked gels if the PEG carries crosslinkable groups. The viscous formulation adheres well to tissue, and has applications as a tissue sealant and in tissue coating, prevention of adhesions, cell immobilization, regeneration of cartilage, bone and other tissue, as well as in controlled delivery of hyaluronic acid to sites in the body. Related materials exhibit similar effects.Type: GrantFiled: November 28, 2001Date of Patent: July 11, 2006Assignee: Genzyme CorporationInventors: Luis Z. Avila, Peter K. Jarrett, Hildegard M. Kramer, C. Michael Philbrook
-
Patent number: 7022343Abstract: Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed in vitro or in vivo. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.Type: GrantFiled: December 27, 2001Date of Patent: April 4, 2006Assignee: Genzyme CorporationInventors: C. Michael Philbrook, James W. Burns, Kevin C. Skinner, Robert J. Miller
-
Patent number: 6923986Abstract: Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.Type: GrantFiled: August 27, 2003Date of Patent: August 2, 2005Assignee: Genzyme CorporationInventors: Chandrashekhar P. Pathak, Shikha P. Barman, C. Michael Philbrook, Amarpreet S. Sawhney, Arthur J. Coury, Luis Z. Avila, Mark T. Kieras